바카라 토토

Research and development in areas with unmet medical needs, fostering a culture of respect, trust, and belonging, and expanding the pipeline for both human and animal health—these are the three pillars guiding Boehringer Ingelheim 바카라 토토’s strategic direction.

In support of this vision, the company recently established a Business Development & Licensing (BD&L) division to collaborate with local researchers, identify novel compounds, and support their advancement into global markets.

Ana-Maria Boie joined Boehringer Ingelheim in 2009 as Marketing Manager for Romania and later served in multiple leadership roles across Romania and Russia. In 2023, she was appointed President and Head of Human Pharmaceuticals at Boehringer Ingelheim 바카라 토토. She also serves on the board of the 바카라 토토 Research-based Pharma Industry Association (KRPIA).

On March 19, Boie met with multinational pharmaceutical journalists to share the company’s strategic goals and vision. She highlighted Boehringer Ingelheim’s plan to launch at least 20 new human medicine indications or drugs globally, including in 바카라 토토, within the next seven years.

What experience have you gained in the pharmaceutical industry, and what were your main priorities and achievements during your first year as President of Boehringer Ingelheim 바카라 토토?

“I started my career as a physician in Romania, practicing in a hospital for two years. My interest in business led me to the pharmaceutical industry, where I worked in marketing roles at AstraZeneca and Pfizer before joining 바카라 토토 Ingelheim in 2009. Since then, I’ve worked across marketing, sales, and ESG roles.

During my first year in 바카라 토토, my priority was simple: to give my best—for patients, customers, and employees. That commitment continues this year. With a medical background, I always keep patients at the center of my decisions.

Currently, I’m focused on three areas: R&D, culture, and pipeline expansion.
First, Boehringer Ingelheim is committed to developing treatments for both humans and animals, with 33 clinical trials ongoing in 바카라 토토.
Second, we’re building a workplace where employees feel fulfilled and supported. Our Employee Assistance Program (EAP) offers counseling and resources to promote well-being. For six consecutive years, we’ve been certified as a Top Employer by the Top Employers Institute.
Third, we’re expanding our pipeline. Jardiance achieved approximately million in sales in 바카라 토토, and our Human Pharma division continues to grow. We’re also expanding indications into areas like heart failure and chronic kidney disease.”

Which products and therapeutic areas are currently the key focus in 바카라 토토, and what are the future plans for the pipeline?
"We aim to launch at least 20 new indications or new drugs globally—including in 바카라 토토—within the next seven years. Our primary therapeutic areas include cardiovascular, renal, and metabolic (CRM) diseases, pulmonary fibrosis (PF), and oncology.

In CRM, we’ve launched treatments such as Jardiance, Trajenta, and Twynsta. We’re preparing to introduce new therapies, including the GLP-1/glucagon dual agonist Survodutide and ASIMPA, a combination of an aldosterone synthase inhibitor with empagliflozin.

In stroke care, Metalyse (tenecteplase) is under regulatory review as a treatment for acute ischemic stroke. We are also awaiting reimbursement for Ofev and are developing Nirandamilast as a follow-up therapy.

In oncology, we’re advancing Jongotininib for non-small cell lung cancer (NSCLC), with regulatory timelines currently being aligned with 바카라 토토n authorities.

For Animal Health, we plan to launch ProZinc, an insulin formulation for dogs and cats, and Senvelgo, a type 2 diabetes treatment for cats, by next year."

A new BD&L division was recently established at the 바카라 토토 office. What led to its creation, and what is its role?

"바카라 토토 is internationally recognized for its strong healthcare system and innovative research. It now ranks among the top five countries globally in R&D capability. This recognition prompted our headquarters in Germany to strengthen local efforts by launching the BD&L division in 바카라 토토.

The division’s mission is to collaborate with 바카라 토토n researchers to identify innovative compounds, support their development, and facilitate global market entry. 바카라 토토 plays a key role in our global strategy, and through this division, we aim to strengthen the innovation ecosystem and uncover new opportunities emerging from 바카라 토토."

How would you characterize the 바카라 토토n pharmaceutical landscape compared to others?
"바카라 토토 has one of the world’s most advanced healthcare systems and ranks fourth in the Asia-Pacific pharmaceutical market. Its single-payer national health insurance system ensures high accessibility to hospitals and physicians.

However, this system also limits flexibility. Innovation is closely tied to government budgets, and even after approval and reimbursement, strict price controls can prevent innovative therapies from being fully recognized. This shortens the window between approval and patent expiration.

According to 2022 data, drug launches in 바카라 토토 are delayed by one to 1.5 years on average. Only 33% of the 460 innovative drugs developed globally between 2012 and 2021 were launched in 바카라 토토.

In contrast, Germany’s multi-payer system allows for broader access—61% of innovative drugs were launched there. While 바카라 토토 offers fast hospital access, this sometimes leads to inefficiencies, as patients can go directly to tertiary hospitals regardless of disease severity. Germany follows a stepwise care model, which supports more efficient use of resources."

Do you believe the government’s initiative to restructure tertiary hospitals could help address these issues?
"It’s hard to say if such a policy is a perfect fit for 바카라 토토, but we support regulatory progress wherever we can. For over 15 years, we’ve partnered with Yuhan Corporation to ensure timely delivery of treatments like Jardiance.

We continue to engage through partnerships and associations. I serve as a board member of KRPIA and chair the Healthcare Committee at the European Chamber of Commerce in 바카라 토토 (ECCK). I also maintain ongoing dialogue with key stakeholders including the Ministry of Food and Drug Safety (MFDS), HIRA, and NHIS to help resolve market access challenges and accelerate the delivery of innovative medicines."

Lastly, how would you like to be remembered when your tenure in 바카라 토토 comes to an end?
"I hope to be remembered as someone trustworthy—both professionally and personally. More than that, I want to leave a positive and meaningful impact on the organization, our partners, and the healthcare community in 바카라 토토."